EntreMed To Highlight ENMD-2076 Kinase Inhibitor At 2008 AACR Annual Meeting

EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced it will present preclinical data for its product candidates ENMD-2076, MKC-1, and ENMD-1198. The data will be presented by EntreMed scientists and collaborators during the American Association for Cancer Research (AACR) Annual Meeting being held April 12-16, 2008 in San Diego, California. Mark R.

More: continued here

Filed under: Cancer on April 13th, 2008